Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms

Authors:

Makoto Asano, Junji Matsui, Murray J Towle, Jiayi Wu, Sharon McGonigle, Marc Hillairet DE Boisferon, Toshimitsu Uenaka, Kenichi Nomoto, Bruce A Littlefield

Abstract:

Eribulin is used in many countries to treat patients with advanced breast cancer or liposarcoma and exerts in vivo anticancer activity under monotherapy conditions against various human tumor xenograft models. Here, eribulin in combination with mechanistically different anticancer agents was evaluated.

Ref: Anticancer Res. 2018 Jun; 38(6):3375-3385. doi: 10.21873/anticanres.12604.

Read the paper here

Share: